As the ischemia-reperfusion injury and inflammatory characteristic of SCD lead to increased ROS formation, enhancing NRF2 protein activity should mitigate these effects and improve clinical outcomes. Here, NFE2L2 is linked to Schnyder corneal dystrophy.